References

Unresolved reference

External reference

10.18356/9789211544350

10.18356/9789211544350 · 2025 · External reference

The HIV/AIDS pandemic: where are we now?

10.1097/qad.0000000000004308 · 2025 · External reference

Unresolved reference

External reference

Discontinuation, suboptimal adherence, and reinitiation of oral HIV pre-exposure prophylaxis: a global systematic review and meta-analysis

10.1016/s2352-3018(22)00030-3 · 2022 · External reference

Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial

10.1016/s0140-6736(22)00538-4 · 2022 · External reference

Twice-yearly lenacapavir for HIV prevention in men and gender-diverse persons

10.1056/nejmoa2411858 · 2025 · External reference

Twice-yearly lenacapavir or daily F/TAF for HIV prevention in cisgender women

10.1056/nejmoa2407001 · 2024 · External reference

The potential of broadly neutralizing antibodies for HIV prevention

10.1002/jia2.26257 · 2024 · External reference

Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition

10.1056/nejmoa2031738 · 2021 · External reference

Cost-effectiveness of pre-exposure prophylaxis for HIV prevention in men who have sex with men in the UK: a modelling study and health economic evaluation

10.1016/s1473-3099(17)30540-6 · 2018 · External reference

Potential cost-effectiveness of community availability of tenofovir, lamivudine, and dolutegravir for HIV prevention and treatment in east, central, southern, and west Africa: a modelling analysis

10.1016/s2214-109x(23)00383-2 · 2023 · External reference

Estimates of adults with indications for HIV pre-exposure prophylaxis by jurisdiction, transmission risk group, and race/ethnicity, United States, 2015

10.1016/j.annepidem.2018.05.003 · 2018 · External reference

Unresolved reference

2024 · External reference

Equity of PrEP uptake by race, ethnicity, sex and region in the United States in the first decade of PrEP: a population-based analysis

2024 · External reference